Cargando…
Body Mass Index, Natriuretic Peptides, and Risk of Adverse Outcomes in Patients With Heart Failure and Preserved Ejection Fraction: Analysis From the TOPCAT Trial
BACKGROUND: The prognostic interrelationship between natriuretic peptide (NP) levels and body mass index (BMI) among patients with chronic stable heart failure with preserved ejection fraction is not well characterized. METHODS AND RESULTS: Participants from the TOPCAT (Treatment of Preserved Cardia...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404179/ https://www.ncbi.nlm.nih.gov/pubmed/30376747 http://dx.doi.org/10.1161/JAHA.118.009664 |
_version_ | 1783400817289592832 |
---|---|
author | Pandey, Ambarish Berry, Jarett D. Drazner, Mark H. Fang, James C Tang, W. H. Wilson Grodin, Justin L. |
author_facet | Pandey, Ambarish Berry, Jarett D. Drazner, Mark H. Fang, James C Tang, W. H. Wilson Grodin, Justin L. |
author_sort | Pandey, Ambarish |
collection | PubMed |
description | BACKGROUND: The prognostic interrelationship between natriuretic peptide (NP) levels and body mass index (BMI) among patients with chronic stable heart failure with preserved ejection fraction is not well characterized. METHODS AND RESULTS: Participants from the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) trial enrolled in the Americas meeting inclusion by the NP stratum were stratified into 4 data‐derived categories by BMI and standardized NP‐z score. Adjusted Cox‐proportional models determined the independent association of BMI, NP‐z score, and BMI/NP categories with composite primary end point, heart failure hospitalization, and all‐cause mortality. The study population included 997 participants. There was a U‐shaped relationship between BMI and NP with elevated NP levels noted at extremes of BMI distribution. There was also a U‐shaped relationship between BMI and risk of adverse clinical outcomes with the lowest risk among patients approximating a BMI of 25 kg/m(2). In contrast, higher NP levels were linearly associated with higher risk of adverse clinical outcomes. For BMI/NP‐based categories, participants in the high BMI/high NP group had greater prevalence of cardiac structural and functional abnormalities and the highest risk of adverse clinical outcomes (hazard ratio for primary end point; 95% confidence interval: 2.29 [1.36–3.84] Reference: low BMI/low NP). CONCLUSIONS: There is a U‐shaped association between BMI and NP levels among patients with chronic heart failure with preserved ejection fraction. Higher NP levels are independently associated with a higher risk of mortality across both high and low BMI strata. Among obese patients with heart failure with preserved ejection fraction, elevated NP levels identify a higher risk phenotype with a significantly increased incidence of both mortality and heart failure hospitalization. |
format | Online Article Text |
id | pubmed-6404179 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-64041792019-03-18 Body Mass Index, Natriuretic Peptides, and Risk of Adverse Outcomes in Patients With Heart Failure and Preserved Ejection Fraction: Analysis From the TOPCAT Trial Pandey, Ambarish Berry, Jarett D. Drazner, Mark H. Fang, James C Tang, W. H. Wilson Grodin, Justin L. J Am Heart Assoc Original Research BACKGROUND: The prognostic interrelationship between natriuretic peptide (NP) levels and body mass index (BMI) among patients with chronic stable heart failure with preserved ejection fraction is not well characterized. METHODS AND RESULTS: Participants from the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) trial enrolled in the Americas meeting inclusion by the NP stratum were stratified into 4 data‐derived categories by BMI and standardized NP‐z score. Adjusted Cox‐proportional models determined the independent association of BMI, NP‐z score, and BMI/NP categories with composite primary end point, heart failure hospitalization, and all‐cause mortality. The study population included 997 participants. There was a U‐shaped relationship between BMI and NP with elevated NP levels noted at extremes of BMI distribution. There was also a U‐shaped relationship between BMI and risk of adverse clinical outcomes with the lowest risk among patients approximating a BMI of 25 kg/m(2). In contrast, higher NP levels were linearly associated with higher risk of adverse clinical outcomes. For BMI/NP‐based categories, participants in the high BMI/high NP group had greater prevalence of cardiac structural and functional abnormalities and the highest risk of adverse clinical outcomes (hazard ratio for primary end point; 95% confidence interval: 2.29 [1.36–3.84] Reference: low BMI/low NP). CONCLUSIONS: There is a U‐shaped association between BMI and NP levels among patients with chronic heart failure with preserved ejection fraction. Higher NP levels are independently associated with a higher risk of mortality across both high and low BMI strata. Among obese patients with heart failure with preserved ejection fraction, elevated NP levels identify a higher risk phenotype with a significantly increased incidence of both mortality and heart failure hospitalization. John Wiley and Sons Inc. 2018-10-31 /pmc/articles/PMC6404179/ /pubmed/30376747 http://dx.doi.org/10.1161/JAHA.118.009664 Text en © 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Research Pandey, Ambarish Berry, Jarett D. Drazner, Mark H. Fang, James C Tang, W. H. Wilson Grodin, Justin L. Body Mass Index, Natriuretic Peptides, and Risk of Adverse Outcomes in Patients With Heart Failure and Preserved Ejection Fraction: Analysis From the TOPCAT Trial |
title | Body Mass Index, Natriuretic Peptides, and Risk of Adverse Outcomes in Patients With Heart Failure and Preserved Ejection Fraction: Analysis From the TOPCAT Trial |
title_full | Body Mass Index, Natriuretic Peptides, and Risk of Adverse Outcomes in Patients With Heart Failure and Preserved Ejection Fraction: Analysis From the TOPCAT Trial |
title_fullStr | Body Mass Index, Natriuretic Peptides, and Risk of Adverse Outcomes in Patients With Heart Failure and Preserved Ejection Fraction: Analysis From the TOPCAT Trial |
title_full_unstemmed | Body Mass Index, Natriuretic Peptides, and Risk of Adverse Outcomes in Patients With Heart Failure and Preserved Ejection Fraction: Analysis From the TOPCAT Trial |
title_short | Body Mass Index, Natriuretic Peptides, and Risk of Adverse Outcomes in Patients With Heart Failure and Preserved Ejection Fraction: Analysis From the TOPCAT Trial |
title_sort | body mass index, natriuretic peptides, and risk of adverse outcomes in patients with heart failure and preserved ejection fraction: analysis from the topcat trial |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404179/ https://www.ncbi.nlm.nih.gov/pubmed/30376747 http://dx.doi.org/10.1161/JAHA.118.009664 |
work_keys_str_mv | AT pandeyambarish bodymassindexnatriureticpeptidesandriskofadverseoutcomesinpatientswithheartfailureandpreservedejectionfractionanalysisfromthetopcattrial AT berryjarettd bodymassindexnatriureticpeptidesandriskofadverseoutcomesinpatientswithheartfailureandpreservedejectionfractionanalysisfromthetopcattrial AT draznermarkh bodymassindexnatriureticpeptidesandriskofadverseoutcomesinpatientswithheartfailureandpreservedejectionfractionanalysisfromthetopcattrial AT fangjamesc bodymassindexnatriureticpeptidesandriskofadverseoutcomesinpatientswithheartfailureandpreservedejectionfractionanalysisfromthetopcattrial AT tangwhwilson bodymassindexnatriureticpeptidesandriskofadverseoutcomesinpatientswithheartfailureandpreservedejectionfractionanalysisfromthetopcattrial AT grodinjustinl bodymassindexnatriureticpeptidesandriskofadverseoutcomesinpatientswithheartfailureandpreservedejectionfractionanalysisfromthetopcattrial |